The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Dren Bio and Sanofi Expand Strategic Collaboration for Next-Generation B-Cell Depletion Therapy
Dec 15, 2025•6 months ago
Contract Type
agreement
Foster CityBiotechnology
Description
Dren Bio has entered into a strategic collaboration with Sanofi to develop a new B-cell depleting therapy aimed at treating autoimmune diseases. The agreement includes an upfront payment of $100 million, and Dren Bio may receive up to $1.7 billion in additional milestone payments.
Company Information
Company
DR-0201
Location
321 GRUNION COURT
Foster City, California, United States
About
DR-0201 is a targeted bispecific myeloid cell engager. It is designed for deep B-cell depletion, particularly in immunology applications. This therapy represents a potential treatment option for diseases like lupus. The acquisition strengthens Sanofi's early pipeline.
Foster CityBiotechnology